Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL501 in Agitation Associated With Delirium in ICU Patients
NCT05313386Phase 2Withdrawn
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dexmedetomidine in agitation, delirium, sponsored by BioXcel Therapeutics, Inc.. Planned start Feb 2021; status: withdrawn.
02
Drugs
dexmedetomidine
03
Conditions
agitationdelirium
Beyond the preview
Go deeper on NCT05313386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05313386.